Levothyroxine is a drug with a narrow therapeutic index. Changing the drug formulation composition or switching between pharmaceutical brands can alter the bioavailability, which can result in major health problems. However, the increased adverse drug reactions have not been fully explained scientifically yet and a thorough investigation of the formulations is needed. In this study, we used a non-targeted analytical approach to examine the various levothyroxine formulations in detail and to reveal possible chemical changes. Ultra-high-performance liquid chromatography coupled with a data-independent acquisition high-resolution mass spectrometry (UHPLC-DIA-HRMS) was employed. UHPLC-DIA-HRMS allowed not only the detection of levothyroxine degradation products, but also the presence of non-expected components in the formulations. Among these, we identified compounds resulting from reactions between mannitol and other excipients, such as citric acid, stearate, and palmitate, or from reactions between an excipient and an active pharmaceutical ingredient, such as levothyroxine-lactose adduct. In addition to these compounds, undeclared phospholipids were also found in three formulations. This non-targeted approach is not common in pharmaceutical quality control analysis. Revealing the presence of unexpected compounds in drug formulations proved that the current control mechanisms do not have to cover the full complexity of pharmaceutical formulations necessarily.

Department of Analytical Chemistry Faculty of Pharmacy in Hradec Králové Charles University Akademika Heyrovského 1203 500 05 Hradec Králové Czech Republic

Laboratoire SOFTMAT Université de Toulouse CNRS UMR 5623 Université Paul Sabatier 118 route de Narbonne 31062 Toulouse Cedex 9 France

See more in PubMed

Khalikova M., Jireš J., Horáček O., et al. What is the role of current mass spectrometry in pharmaceutical analysis? Mass Spectrom. Rev. 2024;43:560–609. PubMed

Kaur N., Suryanarayanan R. Levothyroxine sodium pentahydrate tablets–formulation considerations. J. Pharm. Sci. 2021;110:3743–3756. PubMed

Ledeți I., Romanescu M., Cîrcioban D., et al. Stability and compatibility studies of levothyroxine sodium in solid binary systems-instrumental screening. Pharmaceutics. 2020;12 PubMed PMC

Patel H., Stalcup A., Dansereau R., et al. The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int. J. Pharm. 2003;264:35–43. PubMed

Collier J.W., Shah R.B., Gupta A., et al. Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate. AAPS PharmSciTech. 2010;11:818–825. PubMed PMC

Neu V., Bielow C., Gostomski I., et al. Rapid and comprehensive impurity profiling of synthetic thyroxine by ultrahigh-performance liquid chromatography-high-resolution mass spectrometry. Anal. Chem. 2013;85:3309–3317. PubMed

Neu V., Bielow C., Reinert K., et al. Ultrahigh-performance liquid chromatography-ultraviolet absorbance detection-high-resolution-mass spectrometry combined with automated data processing for studying the kinetics of oxidative thermal degradation of thyroxine in the solid state. J. Chromatogr. A. 2014;1371:196–203. PubMed

Ruggenthaler M., Grass J., Schuh W., et al. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis. J. Pharm. Biomed. Anal. 2017;135:140–152. PubMed

Neu V., Bielow C., Schneider P., et al. Investigation of reaction mechanisms of drug degradation in the solid state: A kinetic study implementing ultrahigh-performance liquid chromatography and high-resolution mass spectrometry for thermally stressed thyroxine. Anal. Chem. 2013;85:2385–2390. PubMed

Benvenga S., Carlé A. Levothyroxine formulations: Pharmacological and clinical implications of generic substitution. Adv. Ther. 2019;36:59–71. PubMed PMC

Kaur N., Suryanarayanan R. Investigating the influence of excipients on the stability of levothyroxine sodium pentahydrate. Mol. Pharm. 2021;18:2683–2693. PubMed

Fliers E., Demeneix B., Bhaseen A., et al. European thyroid association (ETA) and thyroid federation international (TFI) joint position statement on the interchangeability of levothyroxine products in EU countries. Eur. Thyroid. J. 2018;7:238–242. PubMed PMC

Shah H.S., Chaturvedi K., Hamad M., et al. New insights on solid-state changes in the levothyroxine sodium pentahydrate during dehydration and its relationship to chemical instability. AAPS PharmSciTech. 2019;20 PubMed

Hamad M.L., Engen W., Morris K.R. Impact of hydration state and molecular oxygen on the chemical stability of levothyroxine sodium. Pharm. Dev. Technol. 2015;20:314–319. PubMed

Kaur N., Young Jr V.G., Su Y., et al. Partial dehydration of levothyroxine sodium pentahydrate in a drug product environment: Structural insights into stability. Mol. Pharm. 2020;17:3915–3929. PubMed

Bharate S.S., Bharate S.B., Bajaj A.N. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: A comprehensive review, J. Excip. Food Chem. 2010;1:3–26.

Burman K., Hennessey J., McDermott M., et al. The FDA revises requirements for levothyroxine products. Thyroid. 2008;18:487–490. PubMed

Colucci P., Yue C.S., Ducharme M., et al. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur. Endocrinol. 2013;9:40–47. PubMed PMC

Lipp H.-P., Hostalek U. A new formulation of levothyroxine engineered to meet new specification standards. Curr. Med. Res. Opin. 2019;35:147–150. PubMed

Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ. 2018;360 PubMed

Concordet D., Gandia P., Montastruc J.L., et al. Levothyrox® new and old formulations: Are they switchable for millions of patients? Clin. Pharmacokinet. 2019;58:827–833. PubMed PMC

Gottwald-Hostalek U., Uhl W., Wolna P., et al. New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: Results from two pharmacokinetic trials. Curr. Med. Res. Opin. 2017;33:169–174. PubMed

Medsafe, Eltroxin formulation change. medsafe.govt.nz. (Accessed 23 January 2024).

Gottwald-Hostalek U., Tayrouz Y. Real world clinical experience with a new formulation of levothyroxine engineered to meet new and stricter regulatory requirements. Curr. Med. Res. Opin. 2021;37:2093–2098. PubMed

European Pharmacopoeia 11.0, in Levothyroxine sodium, Ph. Eur. 11.0. 2023. European Directorate for the Quality of Medicines Council of Europe; Strasbourg, France: 2023. pp. 3236–3238.

Kazemifard A.G., Moore D.E., Aghazadeh A. Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection. J. Pharm. Biomed. Anal. 2001;25:697–711. PubMed

Sreeramoju M.K., Digenis G.A., May J. Detection and characterization of an unknown impurity in levothyroxine oral solution product: Implications for formulation development and storage. J. Pharm. Sci. 2021;110:682–686. PubMed

Guo J., Huan T. Comparison of full-scan, data-dependent, and data-independent acquisition modes in liquid chromatography-mass spectrometry based untargeted metabolomics. Anal. Chem. 2020;92:8072–8080. PubMed

Fenaille F., Barbier Saint-Hilaire P., Rousseau K., et al. Data acquisition workflows in liquid chromatography coupled to high resolution mass spectrometry-based metabolomics: Where do we stand? J. Chromatogr. A. 2017;1526:1–12. PubMed

Fernández-Costa C., Martínez-Bartolomé S., McClatchy D.B., et al. Impact of the identification strategy on the reproducibility of the DDA and DIA results. J. Proteome Res. 2020;19:3153–3161. PubMed PMC

Worley B., Powers R. Multivariate analysis in metabolomics. Curr. Metabolomics. 2013;1:92–107. PubMed PMC

European Pharmacopoeia 11.0, in Magnesium stearate, Ph. Eur. 11.0. 2023, European Directorate for the Quality of Medicines Council of Europe, Strasbourg, France, pp. 3307–3309.

Calvano C.D., Bianco M., Ventura G., et al. Analysis of phospholipids, lysophospholipids, and their linked fatty acyl chains in yellow lupin seeds (Lupinus luteus L.) by liquid chromatography and tandem mass spectrometry. Molecules. 2020;25 PubMed PMC

Gayral M., Fanuel M., Rogniaux H., et al. The spatiotemporal deposition of lysophosphatidylcholine within starch granules of maize endosperm and its relationships to the expression of genes involved in endoplasmic reticulum-amyloplast lipid trafficking and galactolipid synthesis. Plant Cell Physiol. 2019;60:139–151. PubMed

Lee S.H., BeMiller J.N. Lysophosphatidylcholine identified as channel-associated phospholipid of maize starch granules. Cereal Chem. 2008;85:776–779.

Wang S., Chao C., Cai J., et al. Starch-lipid and starch-lipid-protein complexes: A comprehensive review. Compr. Rev. Food Sci. Food Saf. 2020;19:1056–1079. PubMed

van Hoogevest P. Review - An update on the use of oral phospholipid excipients. Eur. J. Pharm. Sci. 2017;108:1–12. PubMed

Li J., Wang X., Zhang T., et al. A review on phospholipids and their main applications in drug delivery systems. Asian J. Pharm. Sci. 2015;10:81–98.

Kuche K., Bhargavi N., Dora C.P., et al. Drug-phospholipid complex-a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019;20 PubMed

Aleskndrany A., Sahin I. The effects of levothyroxine on the structure and dynamics of DPPC liposome: FTIR and DSC studies. Biochim. Biophys. Acta Biomembr. 2020;1862 PubMed

European Pharmacopoeia 11.0, in Maize starch, Ph. Eur. 11.0. 2023. European Directorate for the Quality of Medicines Council of Europe; Strasbourg, France: 2023. pp. 3311–3312.

Gayral M., Bakan B., Dalgalarrondo M., et al. Lipid partitioning in maize (Zea mays L.) endosperm highlights relationships among starch lipids, amylose, and vitreousness. J. Agric. Food Chem. 2015;63:3551–3558. PubMed

anonymous. Rapport d’analyse de conformité de la nouvelle formulation du Levothyrox effectué par les laboratoires de l’ANSM Actualité - L’ANSM a réalisé dans ses laboratoires plusieurs contrôles sur la composition de Levothyrox nouvelle formule qui ont confirmé sa bonne qualité - Communiqué – ANSM. sante.fr. (Accessed 23 January 2024).

Yousif E.I., Gadallah M.G.E., Sorour A.M. Physico-chemical and rheological properties of modified corn starches and its effect on noodle quality. Ann. Agric. Sci. 2012;57:19–27.

Yang Y., Peng Y., Chang Q., et al. Selective identification of organic iodine compounds using liquid chromatography-high resolution mass spectrometry. Anal. Chem. 2016;88:1275–1280. PubMed

Sleno L. The use of mass defect in modern mass spectrometry. J. Mass Spectrom. 2012;47:226–236. PubMed

Das Gupta V., Odom C., Bethea C., et al. Effect of excipients on the stability of levothyroxine sodium tablets. J. Clin. Pharm. Ther. 1990;15:331–336. PubMed

Gostomski I., Braun R., Huber C.G. Detection of low-abundance impurities in synthetic thyroid hormones by stationary phase optimized liquid chromatography–mass spectrometry. Anal. Bioanal. Chem. 2008;391:279–288. PubMed